Literature DB >> 16557282

Protein-tyrosine phosphatases and cancer.

Arne Ostman1, Carina Hellberg, Frank D Böhmer.   

Abstract

Tyrosine phosphorylation is an important signalling mechanism in eukaryotic cells. In cancer, oncogenic activation of tyrosine kinases is a common feature, and novel anticancer drugs have been introduced that target these enzymes. Tyrosine phosphorylation is also controlled by protein-tyrosine phosphatases (PTPs). Recent evidence has shown that PTPs can function as tumour suppressors. In addition, some PTPs, including SHP2, positively regulate the signalling of growth-factor receptors, and can be oncogenic. An improved understanding of how these enzymes function and how they are regulated might aid the development of new anticancer agents.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16557282     DOI: 10.1038/nrc1837

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  247 in total

1.  PTPD1 supports receptor stability and mitogenic signaling in bladder cancer cells.

Authors:  Annalisa Carlucci; Monia Porpora; Corrado Garbi; Mario Galgani; Margherita Santoriello; Massimo Mascolo; Domenico di Lorenzo; Vincenzo Altieri; Maria Quarto; Luigi Terracciano; Max E Gottesman; Luigi Insabato; Antonio Feliciello
Journal:  J Biol Chem       Date:  2010-10-05       Impact factor: 5.157

2.  Visualizing active-site dynamics in single crystals of HePTP: opening of the WPD loop involves coordinated movement of the E loop.

Authors:  David A Critton; Lutz Tautz; Rebecca Page
Journal:  J Mol Biol       Date:  2010-11-19       Impact factor: 5.469

3.  Enhancing diagnosis, prognosis, and therapeutic outcome prediction of gliomas using genomics.

Authors:  Mahfoud Assem; Zita Sibenaller; Supreet Agarwal; Maha S Al-Keilani; Mohammad A Y Alqudah; Timothy C Ryken
Journal:  OMICS       Date:  2012-03

4.  Analysis of the specific pathways and networks of prostate cancer for gene expression profiles in the Chinese population.

Authors:  Jia-hong Chen; Hui-chan He; Fu-neng Jiang; Julia Militar; Petor-yang Ran; Guo-qiang Qin; Chao Cai; Xi-Bin Chen; Jin Zhao; Zi-yao Mo; Yan-ru Chen; Jian-guo Zhu; Xingyin Liu; Wei-de Zhong
Journal:  Med Oncol       Date:  2011-10-30       Impact factor: 3.064

5.  Cancer-derived mutations in the fibronectin III repeats of PTPRT/PTPrho inhibit cell-cell aggregation.

Authors:  Peng Zhang; Scott Becka; Sonya E L Craig; David T Lodowski; Susann M Brady-Kalnay; Zhenghe Wang
Journal:  Cell Commun Adhes       Date:  2009-12

6.  Selective induction of tumor cell apoptosis by a novel P450-mediated reactive oxygen species (ROS) inducer methyl 3-(4-nitrophenyl) propiolate.

Authors:  Xiaoxiao Sun; Midan Ai; Ying Wang; Shensi Shen; Yuan Gu; Yi Jin; Zuyu Zhou; Yaqiu Long; Qiang Yu
Journal:  J Biol Chem       Date:  2013-02-04       Impact factor: 5.157

7.  GLEPP1/protein-tyrosine phosphatase phi inhibitors block chemotaxis in vitro and in vivo and improve murine ulcerative colitis.

Authors:  Rosanna Pescini Gobert; Monique van den Eijnden; Cedric Szyndralewiez; Catherine Jorand-Lebrun; Dominique Swinnen; Linfeng Chen; Corine Gillieron; Fiona Pixley; Pierre Juillard; Patrick Gerber; Caroline Johnson-Léger; Serge Halazy; Montserrat Camps; Agnes Bombrun; Margaret Shipp; Pierre-Alain Vitte; Vittoria Ardissone; Chiara Ferrandi; Dominique Perrin; Christian Rommel; Rob Hooft van Huijsduijnen
Journal:  J Biol Chem       Date:  2009-02-20       Impact factor: 5.157

8.  PHLPP1 mediates melanoma metastasis suppression through repressing AKT2 activation.

Authors:  Yanlin Yu; Meng Dai; Andrew Lu; Ellen Yu; Glenn Merlino
Journal:  Oncogene       Date:  2018-02-02       Impact factor: 9.867

Review 9.  Role of STAT3 in Genesis and Progression of Human Malignant Gliomas.

Authors:  Zangbéwendé Guy Ouédraogo; Julian Biau; Jean-Louis Kemeny; Laurent Morel; Pierre Verrelle; Emmanuel Chautard
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

10.  Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma.

Authors:  David A Solomon; Jung-Sik Kim; Julia C Cronin; Zita Sibenaller; Timothy Ryken; Steven A Rosenberg; Habtom Ressom; Walter Jean; Darell Bigner; Hai Yan; Yardena Samuels; Todd Waldman
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.